Revolution Medicines

RVMD · NASDAQ

$196.55+$14.40 (+7.91%)TodayMarket closed · Oct 20, 7:47 PM ET

Prev close $182.15

Latest news

NewsOct 20, 1:00 PM ETVandana Singh
Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment
Press releaseOct 20, 8:00 AM ETGlobe Newswire
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
NewsOct 16, 1:06 PM ETVandana Singh
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
Press releaseOct 15, 9:45 AM ETGlobe Newswire
Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
NewsOct 15, 9:43 AM ET
EMA Says CHMP Has Recommended Granting A Marketing Authorisation In European Union For Rasonque (Daraxonrasib) For Metastatic Pancreatic Cancer
Press releaseOct 14, 4:07 AM ETPRNewswire
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
NewsOct 12, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today’s Session
NewsOct 8, 1:19 PM ETPiero Cingari
Stock Market Today: S&P 500 Slips as Oil Spikes 5%, 10-Year Yields Near 5.35%
Press releaseOct 5, 8:00 AM ETGlobe Newswire
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
Press releaseSep 28, 8:00 AM ETPRNewswire
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Press releaseSep 14, 4:05 PM ETGlobe Newswire
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
Press releaseSep 2, 5:50 PM ETGlobe Newswire
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
NewsSep 2, 6:56 AM ETNamrata Sen
Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $400,000 Answer
NewsAug 31, 8:43 AM ETRadhika Anilkumar Nadig
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)
NewsAug 27, 1:13 PM ETVandana Singh
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
NewsAug 27, 11:44 AM ETHenry Khederian
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug
NewsAug 27, 11:08 AM ETVandana Singh
Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results
Press releaseAug 26, 4:33 PM ETPRNewswire
Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution
NewsAug 26, 2:34 PM ETVandana Singh
Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug
NewsAug 26, 10:40 AM ET
FDA Approves First In Class Targeted Therapy For Metastatic Pancreatic Cancer
Press releaseAug 10, 6:00 AM ETBusiness Wire
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
NewsJul 8, 1:35 PM ET
9 Health Care Stocks Whale Activity In Today’s Session
NewsJul 7, 8:42 AM ET
European Medicines Agency's Human Medicines Committee Initiates Phased Review Of Revolution Medicines' Daraxonrasib To Treat Metastatic Pancreatic Cancer
Press releaseJun 3, 8:30 AM ETGlobe Newswire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
NewsMay 31, 10:43 PM ET
Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
NewsMay 19, 9:50 AM ETChandrima Sanyal
GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks
NewsMay 18, 10:12 AM ETSurbhi Jain
Stanley Druckenmiller Dumps Amazon And Alphabet While Loading Up On Commodities, Argentina And Biotech
NewsMay 15, 11:47 AM ETVandana Singh
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseMay 6, 4:02 PM ETGlobe Newswire
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
NewsMay 1, 11:51 AM ET
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
NewsApr 28, 3:43 PM ETPiero Cingari
Stock Market Today: S&P 500 Drops Amid Tech Sell-Off, Oil Climbs To $100 On Hormuz Drama
NewsApr 28, 9:19 AM ETVandana Singh
Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday?
NewsApr 13, 12:36 PM ETAvi Kapoor
Crude Oil Gains 5%; Fastenal Shares Fall After Q1 Earnings
NewsMar 25, 11:20 AM ETVandana Singh
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
NewsFeb 25, 4:12 PM ET
Revolution Medicines: Q4 Earnings Insights
NewsFeb 25, 6:11 AM ET
Earnings Scheduled For February 25, 2026
NewsFeb 24, 9:02 AM ET
Exploring Revolution Medicines's Earnings Expectations
NewsJan 27, 4:13 AM ETAvi Kapoor
Dow Gains Over 300 Points Ahead Of Key Earnings: Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral' Zone
NewsJan 26, 12:15 PM ETAvi Kapoor
Gold Rises Over 2%; US Durable Goods Orders Jump In November
NewsJan 26, 4:48 AM ETAvi Kapoor
Why Baker Hughes Shares Are Trading Higher By Around 4%; Here Are 20 Stocks Moving Premarket
NewsAug 15, 10:45 AM ETAvi Kapoor
This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow

Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

EMA Says CHMP Has Recommended Granting A Marketing Authorisation In European Union For Rasonque (Daraxonrasib) For Metastatic Pancreatic Cancer

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

10 Health Care Stocks With Whale Alerts In Today’s Session

Stock Market Today: S&P 500 Slips as Oil Spikes 5%, 10-Year Yields Near 5.35%

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $400,000 Answer

SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)

When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges

Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug

Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results

Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug

FDA Approves First In Class Targeted Therapy For Metastatic Pancreatic Cancer

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

9 Health Care Stocks Whale Activity In Today’s Session

European Medicines Agency's Human Medicines Committee Initiates Phased Review Of Revolution Medicines' Daraxonrasib To Treat Metastatic Pancreatic Cancer

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks

Stanley Druckenmiller Dumps Amazon And Alphabet While Loading Up On Commodities, Argentina And Biotech

Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report

Earnings Scheduled For May 6, 2026

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug

Stock Market Today: S&P 500 Drops Amid Tech Sell-Off, Oil Climbs To $100 On Hormuz Drama

Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday?

Crude Oil Gains 5%; Fastenal Shares Fall After Q1 Earnings

Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst

Revolution Medicines: Q4 Earnings Insights

Earnings Scheduled For February 25, 2026

Exploring Revolution Medicines's Earnings Expectations

Dow Gains Over 300 Points Ahead Of Key Earnings: Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral' Zone

Gold Rises Over 2%; US Durable Goods Orders Jump In November

Why Baker Hughes Shares Are Trading Higher By Around 4%; Here Are 20 Stocks Moving Premarket

This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday